Zimlovisertib、Ritlecitinib与托法替布单用及联用治疗中重度类风湿关节炎且甲氨蝶呤应答不佳患者的疗效与安全性
这项2期研究将460例中重度活动性类风湿关节炎患者随机分配至zimlovisertib 400 mg联合托法替布11 mg、zimlovisertib 400 mg联合ritlecitinib 100 mg、zimlovisertib 400 mg单药、ritlecitinib 100 mg单药或托法替布11 mg单药治疗24周。第12周时,zimlovisertib联合托法替布组DAS28-CRP平均较基线变化为-2.65(90%CI -2.84至-2.46),优于托法替布单药组的-2.30(90%CI -2.49至-2.11;P=0.032);zimlovisertib联合ritlecitinib组为-2.35(90%CI -2.54至-2.15),与托法替布单药相似。所有治疗耐受性良好。
要点
- zimlovisertib联合托法替布组第12周DAS28-CRP平均较基线变化-2.65,优于托法替布单药组的-2.30(P=0.032)。
- zimlovisertib联合ritlecitinib组DAS28-CRP平均较基线变化-2.35,与托法替布单药组相似,未达统计学显著。
- 治疗中出现的不良事件报告于246例患者(53.5%),托法替布组汇总发生率最高(60例[58.8%]),大多数为轻度。
核心结论
- zimlovisertib联合托法替布在主要终点上比托法替布单药更有效,而zimlovisertib联合ritlecitinib对比托法替布的疗效未达到统计学显著性。
- 所有治疗均耐受性良好。
研究设计与样本
- 这项2期研究将中重度活动性类风湿关节炎患者按4:4:3:3:4随机分配至zimlovisertib 400 mg联合托法替布11 mg、zimlovisertib 400 mg联合ritlecitinib 100 mg、zimlovisertib 400 mg单药、ritlecitinib 100 mg单药或托法替布11 mg单药治疗24周。
- 共460例患者被随机分配。
- 主要终点为第12周DAS28-CRP较基线的变化。
- 监测治疗中出现的不良事件(TEAEs)。
主要发现
- 第12周时,zimlovisertib联合托法替布组DAS28-CRP平均较基线变化为-2.65(90%CI -2.84至-2.46),托法替布单药组为-2.30(90%CI -2.49至-2.11;P=0.032)。
- zimlovisertib联合ritlecitinib组DAS28-CRP平均较基线变化为-2.35(90%CI -2.54至-2.15),与托法替布单药相似。
- 治疗中出现的不良事件报告于246例患者(53.5%),托法替布组汇总发生率最高(n=60[58.8%])。
- 大多数治疗中出现的不良事件为轻度;9例患者(2.0%)报告严重不良事件,10例患者报告严重不良事件。
- 1例接受托法替布的患者因重型COVID-19感染死亡。
关键数值与推荐
- 主要终点为第12周DAS28-CRP较基线的变化。
- zimlovisertib联合ritlecitinib组DAS28-CRP平均较基线变化-2.35(90%CI -2.54至-2.15) vs 托法替布单药组-2.30(90%CI -2.49至-2.11),两组相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to evaluate the efficacy and safety of zimlovisertib (interleukin-1 receptor-associated kinase 4 inhibitor) in combination with ritlecitinib (a JAK3 and tyrosine kinase expressed in hepatocellular carcinoma [TEC] kinase family inhibitors) or tofacitinib (a JAK inhibitor) versus tofacitinib alone. METHODS: This phase 2 study randomized patients with moderate to severe active rheumatoid arthritis to zimlovisertib 400 mg + tofacitinib 11 mg, zimlovisertib 400 mg + ritlecitinib 100 mg, zimlovisertib 400 mg, ritlecitinib 100 mg, or tofacitinib 11 mg (4:4:3:3:4) for 24 weeks. The primary endpoint was change from baseline (CFB) in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP) at week 12. Treatment-emergent adverse events (TEAEs) were monitored. RESULTS: Overall, 460 patients were randomized. At week 12, zimlovisertib + tofacitinib demonstrated a greater magnitude of mean CFB in DAS28-CRP (-2.65; 90% confidence interval [CI], -2.84 to -2.46) versus tofacitinib (-2.30; 90% CI, -2.49 to -2.11; P = 0.032); mean CFB with zimlovisertib + ritlecitinib (-2.35; 90% CI, -2.54 to -2.15) was similar to tofacitinib. TEAEs were reported in 246 patients (53.5%), with the highest aggregate incidence of TEAEs in the tofacitinib group (n = 60 [58.8%]). Most TEAEs were mild; severe TEAEs were reported by 9 patients (2.0%) and 10 patients reported serious AEs. One patient receiving tofacitinib died because of severe COVID-19 infection. Safety profiles were similar across all treatment groups, with no evidence of additive/synergistic issues. CONCLUSION: Zimlovisertib + tofacitinib was more effective than tofacitinib for the primary endpoint, whereas the efficacy of zimlovisertib + ritlecitinib did not achieve statistical significance versus tofacitinib. All treatments were well tolerated.
引用
- Danto SI, Salganik M, Banerjee A, et al. Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2025. PMID: 40223599. doi:10.1002/art.43184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。